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A B S T R A C T   
Quantitative understanding of pharmacokinetics of topically applied ocular drugs requires more research to 
further understanding and to eventually allow predictive in silico models to be developed. To this end, a topical 
cocktail of betaxolol, timolol and atenolol was instilled on albino rabbit eyes. Tear fluid, corneal epithelium, 
corneal stroma with endothelium, bulbar conjunctiva, anterior sclera, iris-ciliary body, lens and vitreous samples 
were collected and analysed using LC-MS/MS. Iris-ciliary body was also analysed after intracameral cocktail 
injection. Non-compartmental analysis was utilized to estimate the pharmacokinetics parameters. The most 
lipophilic drug, betaxolol, presented the highest exposure in all tissues except for tear fluid after topical 
administration, followed by timolol and atenolol. For all drugs, iris-ciliary body concentrations were higher than 
that of the aqueous humor. After topical instillation the most hydrophilic drug, atenolol, had 3.7 times higher 
AUCiris-ciliary body than AUCaqueous humor, whereas the difference was 1.4 and 1.6 times for timolol and betaxolol, 
respectively. This suggests that the non-corneal route (conjunctival-scleral) was dominating the absorption of 
atenolol, while the corneal route was more important for timolol and betaxolol. The presented data increase 
understanding of ocular pharmacokinetics of a cocktail of drugs and provide data that can be used for quanti-
tative modeling and simulation.   
1. Introduction 
Topical application is the most common route of ocular drug 
administration. Bioavailability of drugs after topical administration is 
less than 4% [1–3], since anatomical barriers restrict drug permeation 
into the inner eye (Fig. 1). Moreover, most of the instilled dose is rapidly 
removed from the ocular surface by tear turnover, induced lacrimation, 
and solution drainage into the nasolacrimal duct. During and after the 
solution drainage, the drug is absorbed into systemic circulation across 
the conjunctiva, nasal mucosa and gastrointestinal tract [4–6]. 
Drug absorption into the inner eye takes place through corneal or 
non-corneal pathways. For the corneal route of absorption, drug pene-
trates through the corneal epithelium that constitutes the major barrier 
for drug absorption. Thereafter, the drug reaches the corneal stroma, 
endothelium, and aqueous humor. The corneal route is considered to be 
the most common pathway of topical ocular drug absorption [7–9]. On 
Abbreviations: AUCinf, area under the curve from time zero to infinity; AUClast, area under the curve from the time of dosing to the time of the last measurable 
concentration; Cmax, maximum observed concentration; internal standard, ISTD; tmax, time of maximum observed concentration; t1/2, elimination half-life; MRTinf, 
mean residence time; NCA, non-compartmental analysis. 
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the other hand, drugs may also be absorbed across the conjunctiva and 
sclera (non-corneal route) reaching the ciliary body and iris with limited 
access to the aqueous humor [10–14]. However, the conjunctiva is a 
highly vascularized tissue and a major part of the drug dose may enter 
the blood circulation instead of diffusing into the sclera [14–18]. 
From aqueous humor, the drug may be cleared by aqueous humor 
outflow via trabecular meshwork into Schlemm’s canal [19] or it may 
enter iris-ciliary body blood vessels and then systemic blood circulation 
[20–22]. From the aqueous humor drugs also distribute to the lens and 
vitreous humor, but the concentrations in these tissues are low [13,23]. 
The corneal epithelium is the main anterior barrier for ocular drug 
absorption due to the intercellular tight-junctions, particularly limiting 
permeation of hydrophilic drugs. The acellular corneal stroma allows 
relatively free diffusion of drugs but partitioning of lipophilic drugs from 
the lipoidal epithelium to the hydrophilic stroma may be restricted 
[7–9,24]. 
In fact, the conjunctiva and sclera are more permeable than the 
cornea, being sclera less permeable than conjunctiva [14,24–26]. For 
hydrophilic compounds conjunctiva is ∽ 15–25 times more permeable 
than cornea, and sclera is half as permeable as conjunctiva [25]. 
Although drug diffusion across the conjunctiva and sclera is easier than 
through the cornea [11,14,26], the presence of blood and lymphatic 
flows in the conjunctiva and episclera results in drug elimination from 
the eye into the systemic circulation [27–29]. 
Additionally, iris and ciliary body have a vascular bed with blood 
flows of 62 µl/min and 82 µl/min in rabbits, respectively [21,30]. Iridial 
vessels and ciliary muscle vessels with tight junctions are parts of the 
blood-aqueous barrier. Moreover, the epithelial blood-aqueous barrier 
(posterior iris epithelium and non-pigmented ciliary epithelium) may 
limit drug diffusion further into the vitreous [29,31]. Clearance via the 
iris and ciliary body vessels seems to be faster for lipophilic drugs than 
hydrophilic compounds [32–34]. 
The present study was performed to quantitatively understand the 
ocular pharmacokinetics of the three model drugs: betaxolol, timolol, 
and atenolol cited in decreasing order of lipophilicity (Table 1). The 
compounds were administered as eye drops and intracameral injection. 
Pharmacokinetic parameters were estimated in nine ocular tissues. This 
study provides a comprehensive description of the drug distribution in 
the eyes after topical administration, also including the analysis of the 
corneal vs non-corneal absorption processes. 
2. Material and method 
2.1. Animal experiments 
Animals. Thirty-two albino New Zealand rabbits, age 3–6 months 
and weight 2.8–3.2 kg were use in the experiment sixteen for the topical 
study and sixteen for the intracameral one. The animals were housed in a 
temperature and humidity-controlled environment with a 12/12 light 
/dark cycle. The animals were individually housed and fed a normal 
diet. All rabbits underwent an ocular examination before the experi-
ments. The study comply with ARRIVE (Animal Research: Reporting of 
In Vivo Experiments) guidelines and carried out in accordance with the 
U.K. Animals (Scientific Procedures) Act, 1986 and EU Directive 2010/ 
63/EU for animal experiments. 
Topical administration. The cocktail containing 20 mM atenolol 
(USP reference standard, Sigma), 10 mM betaxolol hydrochloride (USP 
reference standard, Sigma) and 10 mM timolol maleate (USP reference 
standard, Sigma) in phosphate-buffered saline (PBS, Thermofisher Sci-
entific) (pH adjusted to 7.4; 322 mOsm/kg) was administered onto the 
upper cornea-scleral limbus of both eyes (25 µl/eye) in each rabbit as 
previously reported [1]. The tear fluid samples of 1 µl were withdrawn 
from each eye with disposable microcapillaries (Microcaps, Drummond 
Scientific). Corneal epithelium, corneal stroma with endothelium, 
bulbar conjunctiva, anterior sclera, aqueous humor, iris-ciliary body, 
lens, and vitreous humor were collected and weighted at 5, 10, 20, 30, 
60, 120, 180 and 240 min, and the number of eyes at each time point 
was four (n = 4). 
Intracameral administration. A volume of 5 µl of the cocktail so-
lution with atenolol, timolol and betaxolol (each at 1 mM in PBS) was 
injected into the anterior chamber (aqueous humor) of the rabbit eye 
[32]. The animals were sacrificed by injecting into the marginal ear vein 
a lethal dose of pentobarbital (Mebunat vet 60 mg/ml; Orion Pharma, 
Finland). In these experiments, aqueous humor and iris-ciliary body 
samples were collected and weighted at time points 10, 20, 30, 60, 120, 
180 and 240 min with number of eye per each time point 4 (n = 4) as 
previously described [32]. All samples were cooled on ice following 
storage at − 80 ◦C until analyses. 
Dissection of ocular tissues. The excised eyeballs were dipped to 
PBS. Firstly, the corneal epithelium was collected from the corneal 
surface by gently scraping with a scalpel blade. Then, a piece of 
approximately 5 mm × 5 mm size of bulbar conjunctiva was collected 
with small scissors by first cutting a small hole through conjunctiva from 
the limbus, detaching the conjunctiva from the surface of the eye and 
Fig. 1. Ocular absorption, distribution and elimi-
nation routes after topical administration. A: 
Anatomy of the eye. B: Absorption, distribution and 
clearance pathways after topical administration. 1: 
corneal absorption; 2: a) conjunctival absorption into 
conjunctival blood vessels reaching the systemic cir-
culation and b) conjunctiva-scleral absorption into 
ciliary body and iris; 3: tear flow and extra volume 
drainage by the nasolacrimal system; 4: clearance 
from trabecular meshwork into Schlemm’s canal; 5: 
distribution into the ciliary body and iris and the 
blood circulation therein; 6: distribution to the lens. 
(https://www.publicdomainpictures.net/en/view- 
image.php?image=130389&picture= medical-eye).   
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finally removing the conjunctival piece. The sclera was cut open from 
the same spot as the conjunctiva was collected, and a ~ 5 mm × 5 mm 
piece of anterior sclera was removed. From the scleral piece, remaining 
extraocular tissues and retina were removed with scissors. Then, the 
anterior part (corneal stroma with endothelium, iris-ciliary body and 
lens) was detached from the posterior tissues (vitreous, retina, choroid, 
sclera) by cutting with scissors 2 mm posterior from the limbus. Cutting 
was started from a pre-made hole in the sclera, enabling removal of the 
iris-ciliary body and lens with the cornea. Then, lens and iris-ciliary 
body were collected with tweezers, and the sclera was cut off from the 
corneal stroma and endothelium with scissors to obtain the corneal 
sample. From the posterior part, vitreous was dissected on a separate 
dish by gently pulling the vitreous from the eyecup with tweezers. When 
necessary, the vitreous sample was cleaned from retinal contamination 
with tweezers and scissors to obtain a clean vitreous sample. 
2.2. LC-MS/MS analyses 
The corneal epithelial samples were lysed by adding 38-fold volume 
of 0.1 N NaOH (based on the sample weight) and then pipetted and 
vortexed until homogenous tissue lysate was obtained. Corneal stroma- 
endothelium, bulbar conjunctiva and anterior sclera samples were cut 
into smaller pieces with scalpel before homogenization. The samples 
were transferred to the 2 ml or 7 ml tubes containing 2.8 mm ceramic 
beads (Omni International, USA), PBS buffer was added and the tissues 
were homogenized at 4–6 m/s speed in total for 0.5–12 min using Bead 
Ruptor Elite (Omni Internationals, USA). For corneal stroma- 
endothelium, bulbar conjunctiva, anterior sclera, iris ciliary body and 
lens the homogenization was performed in two steps and PBS buffer was 
added between steps. Homogenization conditions were optimized for 
each tissue to obtain smooth tissue homogenate, suitable for pipetting 
(Supplementary Table S1). Some samples of early time points (corneal 
epithelium, corneal stroma-endothelium, bulbar conjunctiva, iris-ciliary 
body) were diluted with similarly prepared blank tissue homogenate. 
One part of each sample was mixed with 3 parts of internal standard 
solution (e.g. 30 µl of sample and 90 µl) by vortexing for 10 sec. Internal 
standard (ISTD) solution contained 50 ng/ml atenolol-d7 (Toronto 
Research Chemicals, Canada), 5 ng/ml betaxolol-d5 (Toronto Research 
Chemicals, Canada), 5 ng/ml rac timolol-d5 maleate (Toronto Research 
Chemicals, Canada), 1% formic acid in acetonitrile. In the case of the 
vitreous samples, one part of the vitreous homogenate was mixed with 
one part of ISTD solution. All the samples were incubated at RT for 10 
min and thereafter centrifuged (10 min, +4◦C, 13 000 rpm). The su-
pernatant was collected for the LC-MS/MS analysis. Standards 
(0.5–4000 nM, in duplicates) and quality controls (in triplicates, 4–6 
levels) were prepared from the drug cocktail (containing 20 mM aten-
olol, 10 mM timolol maleate and 10 mM betaxolol hydrochloride in PBS) 
into blank tissue homogenates in the same way as the samples were 
treated. 
Tear fluid samples were prepared in the same way as aqueous humor 
samples in our previous article [32] with the exception that ISTD solu-
tion was 50 ng/ml atenolol-d7, 5 ng/ml betaxolol-d5, 5 ng/ml rac 
timolol-d5 maleate, 1% formic acid in 50% acetonitrile. Tear fluid 
samples were first diluted with ISTD solution (dilution factors were 
20–4000) to achieve final concentrations in the range of calibration 
curve (0.1 – 5000 nM). Standards and quality controls were prepared by 
diluting the beta-blocker cocktail in PBS by ISTD solution. Additional 
quality controls (250 nM, n = 2), which were prepared in similar manner 
as tear fluid samples (dilution of tear fluid 1:20 and 1:2000 with ISTD 
solution), were included into LC-MS/MS analysis. 
All samples, standards and quality controls were analysed by LC-MS/ 
MS (Agilent 1290 liquid chromatograph and Agilent 6495 triple quad-
rupole mass spectrometer, Agilent Technologies Inc., USA) as described 
earlier [32]. The calibration curves were generated using 7–13 
Table 1 
Physicochemical properties of atenolol, timolol and betaxolol (calculated with ACD/Percepta, version 2254, Advanced Chemistry Development, Inc. Toronto, Canada).  
Drugs Molecular structure Molecular weight Log D7.4 Polar surface area Hydrogen bond donor 
Atenolol 266.34 − 1.85 84.5 4 
Timolol 316.42 − 0.35 107.9 2 
Betaxolol 307.43 0.77 50.7 2  
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concentration levels. Mean accuracy of the standards of most standard 
curve points (≥78%) was 80–120%. The accuracy of QC samples was 
80–120% for ≥ 67% of quality controls. For additional tear fluid QC 
samples the accuracy was 86–110%. 
2.3. Pharmacokinetic analysis 
Mean concentration–time profiles of drugs in the tissues were ana-
lysed using non-compartmental analysis (NCA) with Phoenix WinNonlin 
(build 8.1, Certara L.P.) using linear–linear trapezoidal interpolation. 
The following pharmacokinetic parameters were estimated: area under 
the curve (AUC) from time zero until last sampling point (AUClast), total 
AUC until infinity (AUCinf), mean residence time (MRTinf), peak con-
centration (Cmax), time to peak concentration (tmax) and elimination 
half-life (t1/2). The AUCinf and MRTinf were reported for the tissues with 
the terminal phase of the concentration–time profiles longer than two 
half-lives. 
3. Results 
The dose-normalized (to 250 nmol) concentration–time profiles for 
the topically applied drugs in eight ocular tissues (this study) and the 
aqueous humor (from our previous study) [1] are shown in Fig. 2. The 
aqueous humor [32] and iris-ciliary body (present study) concen-
tration–time profiles after intracameral administration of 5 nmol of 
atenolol, timolol and betaxolol are presented in Supplementary Fig. S1. 
Betaxolol concentrations were higher than the levels of timolol and 
atenolol in most tissues, but in the tear fluid atenolol concentrations 
were the highest (Fig. 2, Supplementary Fig. S2). Drug concentrations in 
various tissues show a wide range as the concentrations in the corneal 
epithelium are at least 1000 times higher than in the vitreous. 
The pharmacokinetic parameters for the topical and intracameral 
beta-blockers are listed in Table 2 (see in Supplementary Table S2 the 
original data without dose normalization). As expected, the MRT values 
are shorter in the tear fluid than in the other tissues. In some tissues, the 
MRT values are relatively constant regardless of the drug (e.g. corneal 
epithelium), while in other tissues (e.g. aqueous humor, corneal stroma- 
endothelium, vitreous, iris-ciliary body) hydrophilic atenolol has longer 
retention times than the more lipophilic timolol and betaxolol (Sup-
plementary Fig. S3). 
The AUCinf values of the drugs are shown in Fig. 3. The data shows 
that AUCinf values span over the range of four orders of magnitude from 
tear fluid to lens and vitreous. Atenolol has the highest AUCinf in tear 
fluid whereas betaxolol has the highest AUC values in the corneal 
epithelium and other tissues. The AUCinf values of three drugs are higher 
in the iris-ciliary body than in the aqueous humor. AUCinf values of 
Fig. 2. Concentration-time profiles of drugs in nine ocular matrices (A-I) of rabbits after topical administration of atenolol (250 nmol dose-normalized), timolol (250 
nmol dose), and betaxolol (250 nmol dose). Mean drug concentrations ± standard errors of the mean (n = 3–4) are presented. Timolol concentration could not be 
quantified in the lens due to the lack of a reliable control sample. 




Pharmacokinetic parameters estimated with NCA analysis of the three beta-blockers concentrations in nine ocular tissues after topical administration including the aqueous humor [1], and iris-ciliary body, and aqueous 
humor [2] after intracameral administration with a dose-normalization to 250 nmol.   
Atenolol Timolol Betaxolol 
Topical AUCinf AUClast Cmax tmax t1/2 MRT AUCinf AUClast Cmax tmax t1/2 MRT AUCinf AUClast Cmax tmax t1/2 MRT  
(min*nmol/ml or g) (nmol/ml or g) (min) (min*nmol/ml or g) (nmol/ml or g) (min) (min*nmol/ml or g) (nmol/ml or g) (min) 
Tear fluid 71720 71542 3240 5 45 9 58398 58311 2345 5 45 6 39799 39769 1398 5 40 5 
Corneal epithelium 3387 3361 159 5 34 63 9642 9611 171 5 27 62 24760 24712 348 5 24 60 
Corneal stroma -endothelium 627 562 5.98 5 62 104 819 774 13.2 5 53 74 978 949 19.6 5 43 57 
Bulbar conjunctiva 208 198 3.24 20 52 74 234 228 6.55 5 47 59 378 372 11.3 5 42 50   
164*      197*      334*     
Anterior sclera -  0.41 5 84 - 71.5 67.7 2.60 5 59 72 111 108 4.70 5 47 55   
39.1*      57.3*      96.7*     
Iris-ciliary body 72.4 66.2 0.63 60 56 105 213 201 3.07 5 52 77 398 390 7.52 5 39 55   
49.5*      169*      352*     
Aqueous humor 19.6 15.8 0.15 60 87 148 151 149 1.97 20 37 64 252 251 3.76 20 29 54 
Lens 3.65 3.35 0.03 60 53 112 ** ** ** ** ** ** 32.8 27.2 0.27 20 88 133 
Vitreous humor 4.22 3.69 0.04 20 74 118 8.13 7.52 0.11 5 61 89 8.53 7.97 0.13 5 56 80 
Intracameral                   
Iris-ciliary body 9939 7624 85.8 60 85 149 4615 4456 106 10 47 60 5013 4907 145 10 41 51 
Aqueous humor 28711 26397 365 20 59 84 10895 10819 204 20 31 45 6520 6486 142 20 31 39 
TOP: ICB/AH 3.69      1.41      1.58      
IC: ICB/AH 0.35      0.42      0.77      
AUCinf: Area under the curve from 0 to infinity. 
AUClast: Area under the curve from 0 to last sampling time (240 min) unless otherwise indicated. 
Cmax: Maximum concentration. 
tmax: Time to peak concentration. 
t1/2: Elimination half-life. 
MRT: Mean residence time to infinity. 
* AUClast until 120 min. 
** timolol could not be quantified due to the lack of a reliable control sample. 
-: unreliable estimate because the concentration-time profile was shorter than two half-lives. 
ICB/AH: AUCinf ratio between iris-ciliary body and aqueous humor after topical (TOP) and intracameral (IC) administrations. 
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betaxolol in aqueous humor, corneal epithelium, and iris-ciliary body 
were 12, 7, and 5.5 times higher than the values of atenolol, while 
betaxolol had 2, 2.5, and 1.9 higher values than timolol. 
The AUCinf ratios between the adjacent tissues are presented in 
Fig. 4. Lipophilic betaxolol shows the highest partitioning from tear fluid 
to the corneal epithelium and bulbar conjunctiva. Likewise, it shows the 
highest partitioning from sclera to iris-ciliary body. Interestingly, aten-
olol shows the highest ratios of iris-ciliary body/aqueous humor, corneal 
stroma-endothelium/epithelium and vitreous/aqueous humor ratios. 
Overall, concentration ratios between neighboring tissues show wide 
range of values from ≈ 0.001 to less than 10. 
Iris-ciliary body concentration–time profiles after topical and intra-
cameral administration of the drugs are presented in Supplementary Fig. 
S4 . Atenolol shows a bigger difference than timolol and betaxolol be-
tween the iris-ciliary body concentrations after topical and intracameral 
administrations. Differences are also seen among AUCinf ratios between 
iris-ciliary body and aqueous humor (Table 2). 
4. Discussion 
A cocktail approach was utilized to estimate the pharmacokinetic 
behavior of betaxolol, timolol and atenolol in the ocular tissues of the 
rabbit eye. The current study provides pharmacokinetic data and pa-
rameters to better understand tissue exposure, partitioning and elimi-
nation of the drugs. 
4.1. Corneal drug absorption 
In the tear fluid, atenolol shows higher levels than the more lipo-
philic timolol and betaxolol (Table 2, Fig. 2A and 3, Supplementary Fig. 
S2A). Flow patterns of the instilled solution is identical for all drugs in 
this study as a cocktail approach was used. Thus, the differences among 
three drugs can be explained by their different rates of elimination from 
lacrimal fluid across the membranes (cornea, conjunctiva); with the 
more lipophilic compounds betaxolol and timolol having higher 
permeability [14,35]. Since the short initial half-life in the tear fluid 
cannot be obtained using the NCA analysis, the reported half-lives in 
Table 2 correspond to later phases in the disposition process that may 
involve drug equilibration to the tissues, and back-diffusion to the 
lacrimal fluid [11,24,36]. 
In the corneal epithelium, betaxolol and timolol showed higher 
concentrations and corneal partitioning than atenolol, which is expected 
due to their increased lipophilicity. Corneal stroma is not posing an 
anatomical barrier for diffusion of small molecules [7]. Interestingly, it 
seems that hydrophilic atenolol has higher corneal stroma-endothelium 
/ aqueous humor ratio and longer MRT in the corneal stroma- 
endothelium (inset of Fig. 4, Table 2). This may reflect lower perme-
ability of atenolol in corneal endothelium as compared to timolol and 
betaxolol. 
Betaxolol had the highest AUCinf value in the aqueous humor (Fig. 3, 
Table 2), probably due to its lipophilicity and higher corneal perme-
ation. Concentration profiles of betaxolol and timolol had similar first- 
order decline in aqueous humor and in corneal-epithelium (Supple-
mentary Fig. S2A). This supports the notion that corneal absorption is 
the main route of drug absorption to the aqueous humor and corneal 
epithelium forms a drug depot after eye drops instillation [1,9,12]. On 
the contrary, the concentration profile of atenolol is flatter, reflecting 
Fig. 3. The AUCinf values of betaxolol, timolol and atenolol in the ocular tissues 
after topical eye drop instillation to the rabbit eyes with a dose-normalization to 
250 nmol. For anterior sclera AUClast = 120 min values are shown (*). 
Abbreviation: Cor = cornea. 
Fig. 4. The AUCinf ratios among neighboring tis-
sues after topical eye drop instillation of betaxolol, 
timolol and atenolol to the rabbit eyes. The inset 
shows AUCinf ratios in the direction of drug accu-
mulation into corneal epithelium, corneal stroma- 
endothelium and bulbar conjunctiva. The AUCinf 
(Table 2) was used except for anterior sclera-related 
ratios when AUClast=120min was used (*). Abbrevia-
tions: CorEpi = corneal epithelium, TF = tear fluid, 
Stroma-Endo = corneal stroma-endothelium, AH =
aqueous humor, Bulb-Conj = bulbar conjunctiva, 
Ant-Sclera = anterior sclera, ICB = iris-ciliary body, 
and VH = vitreous humor.   
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the first-order decline rate in the corneal stroma-endothelium (Supple-
mentary Fig. S2A). This suggest that corneal stroma, not epithelium, is a 
depot site for atenolol following topical administration. 
As expected [7,9] lipophilicity plays a positive impact on the corneal 
drug absorption to the aqueous humor. From the aqueous humor, the 
drugs distribute into the iris-ciliary body, lens, and vitreous. It is known 
that hydrophilic atenolol has lower clearance from the aqueous humor 
than timolol and betaxolol [32], this is in line with the longer MRT in the 
aqueous humor. 
4.2. Non-corneal drug absorption 
Drugs permeate from tear fluid to the conjunctiva and in this case 
also betaxolol showed the highest conjunctival concentrations, followed 
by timolol and atenolol (Fig. 2, Table 2, Supplementary Fig. S2B). 
Lipophilic drugs permeate faster into cellular conjunctiva, but they are 
also eliminated faster into the systemic circulation from the conjunctiva 
[11,14,26]. For this reason, the conjunctival AUCinf values are much 
lower than the non-vascular corneal ones and the AUCinf differences 
among the drugs are also smaller in conjunctiva than in cornea (Fig. 2, 
Fig. 3, Table 2). 
Scleral kinetics of betaxolol and timolol showed similar decline as in 
the bulbar conjunctiva, and no differences among drugs were seen in the 
AUClast=120 min ratios between these two tissues (Fig. 4). From sclera the 
drugs may reach iris-ciliary body. Atenolol concentrations were slightly 
higher in the iris-ciliary body than the sclera, for the more lipophilic 
compounds there was a bigger difference in the iris-ciliary body 
compared to scleral concentrations (Table 2, Fig. 3), possibly due to 
entry of some drug from the aqueous humor to the iris-ciliary body 
[20,22,37]. Higher AUCinf ratio of hydrophilic atenolol between iris- 
ciliary body and aqueous humor may be partly due to its higher non- 
corneal entry into iris-ciliary body as compared to timolol and betax-
olol. The slower clearance of hydrophilic atenolol than timolol and 
betaxolol via iris blood vessels could also contribute in the cited higher 
AUCinf ratio of atenolol [32]. 
After intracameral administration, the concentration time profiles of 
timolol and betaxolol in aqueous humor and iris-ciliary body are quite 
similar, but atenolol shows different kinetic behaviour: slower distri-
bution and elimination in the iris-ciliary body (Supplementary Fig. S1). 
This behavior reflects the slower permeation of atenolol into the blood- 
aqueous barrier. As intracameral administration results in iridial drug 
distribution only from the aqueous humor, it is interesting to compare 
these data with the topical eye drop data that involves also non-corneal 
drug delivery. Comparison of the AUCinf ICB/AH ratios of hydrophilic 
atenolol after topical (3.69) and intracameral (0.35) administrations 
reveals ten times higher ratio for topical administration, suggesting the 
importance of non-corneal atenolol absorption. The difference was only 
2–3-fold for more lipophilic timolol and betaxolol. Therefore, atenolol 
has the lowest AUCinf in the iris-ciliary body target tissue after topical 
administration, but the highest contribution from non-corneal route of 
absorption. Non-corneal absorption was earlier seen also for topical 
suspension of brinzolamide [2], and timolol insert placed in the 
conjunctival sac [34]. Comparisons of these ratios inform about the 
relative importance of the non-corneal route, but these values do not 
give absolute non-corneal contributions, because trans-corneal delivery 
to the iris-ciliary body may differ from the iris-ciliary body distribution 
after intracameral injection. 
4.3. Lens and vitreous 
Atenolol and betaxolol distributed to a lower extent from aqueous 
humor into the lens (Fig. 3). Poor lenticular distribution is due to its tight 
structure that resulted in low lens/buffer partition coefficients for 
various drugs in vitro [23]. Thus, the lens acts as a barrier between the 
anterior chamber and vitreous, but it does not seem to act as a drug 
reservoir. 
Drugs may distribute also from the aqueous humor into the vitreous 
humor, and the expected route is via permeation across the iris-ciliary 
body, since lens is quite impermeable and aqueous humor flow from 
posterior to anterior direction prevents drug transfer to the vitreous. The 
drug concentrations and AUCinf values in the vitreous humor are 1–2 
orders of magnitude lower than in the aqueous humor (Figs. 2-3) as it 
has been observed earlier [34,38,39]. Ratio of AUCinf values between 
vitreous and aqueous humor is several times higher for atenolol than for 
timolol and betaxolol (Fig. 4). Atenolol has much lower clearance to the 
blood flow in the iris-ciliary body than timolol and betaxolol [32], since 
atenolol does not permeate across the walls of the uveal blood vessels 
that represent the blood-aqueous barrier. Therefore, atenolol may reach 
the vitreous at a higher level than timolol and betaxolol. However, the 
concentrations of all three drugs in the vitreous humor are four orders of 
magnitude lower than in the tear fluid at early times and bioavailability 
of topically applied drugs to the vitreous humor is negligible (Fig. 2). 
5. Conclusion 
The present study shows the influence of lipophilicity on ocular 
pharmacokinetic processes after topical administration and gives in-
sights on the relative contributions of the corneal and non-corneal routes 
of drug absorption. Detailed information on the disposition of three 
drugs to nine different ocular tissues over time following topical 
administration can be used to build physiological models of drug dis-
tribution in the eye with the ultimate aim of developing predictive in 
silico models that would allow the number of preclinical studies in ani-
mals to be reduced or replaced. Ultimately speeding up ocular drug 
development. 
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